Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX 09:49:12 2024-02-28 am EST 5-day change 1st Jan Change
161.1 USD +0.06% Intraday chart for Johnson & Johnson +1.45% +2.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
J&J: FDA approves new formulation of Imbruvica CF
Legend Biotech Says European Panel Recommends Label Expansion of Carvykti for Treatment of Multiple Myeloma MT
J&J's Acquisition of Ambrx Biopharma Completes Hart-Scott-Rodino Waiting Period MT
J&J: FDA approval for Tecvayli in myeloma CF
ViiV's Long-acting Injectable HIV Drug Shown More Effective than Daily Pills in Phase 3 Study MT
Johnson & Johnson's Application for Tecvayli Gets FDA Approval DJ
Bi-weekly dose of Johnson & Johnson's blood cancer therapy gets US FDA approval RE
Johnson & Johnson Announces the U.S. Food and Drug Administration Approves the Supplemental Biologics License Application for TECVAYLI®? CI
Alvotech Settles With Johnson & Johnson to Launch AVT04 in Japan, Canada, Europe MT
MeiraGTx to Receive $50 Million Milestone Payment from J&J's Janssen Under Bota-Vec Deal MT
Smith & Nephew Q4 Margin in Focus, Outlook Upgrade Likely, RBC Says MT
J&J: towards best practices in wound care CF
J&J: applies to the EMA for a new indication for Rybrevant CF
US Senate Democrats grill pharma CEOs on drug prices RE
Tylenol maker Kenvue forecasts annual profit below estimates after weak quarter RE
Johnson & Johnson Announces Publication in the New England Journal of Medicine of the Phase 2b FRONTIER 1 Trial Results for JNJ-2113 CI
GE HealthCare forecasts 2024 profit largely above estimates RE
LivaNova Names Vladimir Makatsaria as Chief Executive MT
J&J: encouraging results for nipocalimab CF
Johnson & Johnson Reports Positive Topline Results for Nipocalimab from Phase 3 Pivotal Study in Generalized Myasthenia Gravis and Phase 2 Study in Sjögren's Disease CI
US sends drugmakers initial offers in Medicare price talks AN
Colgate-Palmolive: Attractive dividend yields Our Logo
US government sends initial offers for Medicare drug price cuts RE
Stryker forecasts strong 2024 as uptick in surgeries lift demand for devices RE
Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seek Approval of DARZALEX FASPRO CI
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
161 USD
Average target price
174.2 USD
Spread / Average Target
+8.24%
Consensus
  1. Stock
  2. Equities
  3. Stock Johnson & Johnson - Nyse
  4. News Johnson & Johnson
  5. Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW